Chemistry:Nemorexant

Nemorexant

Clinical data
Other names	ACT-541468
Routes of administration	By mouth
Drug class	Orexin antagonist
Identifiers
IUPAC name [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone
CAS Number	1505484-82-1
PubChem CID	91801202
ChemSpider	64854514
UNII	LMQ24G57E9
Chemical and physical data
Formula	C23H23ClN6O2
Molar mass	450.927 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl
InChI InChI=1S/C23H23ClN6O2/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28)/t23-/m0/s1 Key:NBGABHGMJVIVBW-QHCPKHFHSA-N

Nemorexant (developmental code name ACT-541468) is a dual orexin receptor antagonist (DORA) which was originated by Actelion Pharmaceuticals and is under development by Idorsia Pharmaceuticals for the treatment of insomnia. It acts as a selective dual antagonist of the orexin receptors OX₁ and OX₂. As of June 2018, nemorexant is in phase III clinical trials for the treatment of insomnia.

See also

• List of investigational sleep drugs

External links

• Nemorexant - AdisInsight